FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
|Articles|May 2, 2020
- Pharmaceutical Technology-05-02-2020
- Volume 44
- Issue 5
Pre-Packed Columns
Tosoh Bioscience introduced the SkillPak 1 mL and 5 mL pre-packed columns for fast method development and resin screening of monoclonal antibodies, antibody constructs, oligonucleotides, proteins, and viruses.
Tosoh Bioscience introduced the SkillPak 1 mL and 5 mL pre-packed columns for fast method development and resin screening of monoclonal antibodies, antibody constructs, oligonucleotides, proteins, and viruses.
The columns come pre-packed with Toyopearl, TSKgel, or Ca++Pure-HA process chromatography media and are ready for use immediately. Additionally, the high performance, scalable columns are available with short delivery times in affinity, anion and cation exchange, hydrophobic interaction, and size exclusion chromatographic modes. Peak performance is guaranteed, according to the company, and the columns can be operated directly with low- or medium-pressure liquid chromatography systems.
Articles in this issue
over 6 years ago
Modern Drug Manufacturing Key to COVID-19 Responseover 6 years ago
How Fast Is Too Fast?over 6 years ago
Starting a Career in the Bio/Pharmaceutical Industryover 6 years ago
Can We Teach an Old Drug New Tricks?over 6 years ago
Good Manufacturing Practices: Aseptic and Sterile Processingover 6 years ago
Small-Volume Conversion Kit for Bathless Dissolution Testersover 6 years ago
Inline High Shear Mixersover 6 years ago
Laser-Marked Smart ContainersRelated to this article
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.